semaglutide lean mass loss Can We Improve the Quality of Weight by Augmenting Fat Loss while Preserving Mass? The BELIEVE Study of Bimagrumab + (Preview) Semaglutide and Protein for Weight

HIMS stock has risen 14% over the past year

Its FDA approval came after regulatory delays related to these cardiovascular concerns, and it is used selectively in patients in whom the benefits of rapid bone density improvement outweigh the cardiovascular risks

Potential of parameters of iron metabolism for the diagnosis of anemia of inflammation in the critically ill

In December 2024, the companies entered into an exclusive global license agreement for Hansoh Pharms HS-10535 (now MK-4082), which gave Merck an exclusive global license to develop, manufacture, and commercialize the drug in a $2.0-billion deal ($112 million upfront and milestone payments of up to $1.9 billion)